1. Home
  2. ZNB vs KALA Comparison

ZNB vs KALA Comparison

Compare ZNB & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zeta Network Group Class A Ordinary Shares

ZNB

Zeta Network Group Class A Ordinary Shares

N/A

Current Price

$0.43

Market Cap

2.8M

ML Signal

N/A

Logo KALA BIO Inc.

KALA

KALA BIO Inc.

N/A

Current Price

$3.04

Market Cap

2.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ZNB
KALA
Founded
2002
2009
Country
China
United States
Employees
N/A
N/A
Industry
Engineering & Construction
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8M
2.5M
IPO Year
2018
2017

Fundamental Metrics

Financial Performance
Metric
ZNB
KALA
Price
$0.43
$3.04
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 2.6M
164.5K
Earning Date
10-19-2026
12-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 67.39
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.10
$0.07
52 Week High
$9.78
$191.00

Technical Indicators

Market Signals
Indicator
ZNB
KALA
Relative Strength Index (RSI) 35.09 77.25
Support Level $0.22 $2.07
Resistance Level $1.93 $3.71
Average True Range (ATR) 0.21 0.14
MACD -0.01 0.38
Stochastic Oscillator 6.67 73.26

Price Performance

Historical Comparison
ZNB
KALA

About ZNB Zeta Network Group Class A Ordinary Shares

Zeta Network Group consist principally of cryptocurrency mining. The company conducts business as two operating segments which comprise of consulting services and cryptocurrency mining. Majority of revenue comes from cryptocurrency mining segment.

About KALA KALA BIO Inc.

Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Share on Social Networks: